Sep. 30, 2025 Others

Japan Airlines Featured Our iPS Cell-Derived Product Transportation Project on Their Website.

Sumitomo Pharma is advancing the commercialization of regenerative medicine and cell therapy products utilizing iPS cells (induced pluripotent stem cells), in collaboration with academia, Sumitomo Chemical Co., Ltd., RACTHERA Co., Ltd., and S-RACMO Co., Ltd. We are pleased to announce that our project to transport products under development to the United States has been featured on Japan Airlines’ case study page.

This case highlights the extremely challenging task of transporting live (non-frozen) iPS cell-derived products from our manufacturing facility at the Central Research Institute (Suita City, Osaka Prefecture) to a U.S. administration site within 24 hours, and the efforts undertaken to overcome this challenge.

Sumitomo Pharma will continue to strengthen partnerships and provide solutions leveraging cutting-edge technologies and expertise, in order to deliver new treatment possibilities to patients.